Published in J Bone Miner Res on May 01, 2011
Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J Bone Joint Surg Am (2013) 2.29
Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity. J Clin Endocrinol Metab (2013) 1.69
Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res (2013) 1.66
Atypical femoral fractures: epidemiology, etiology, and patient management. Curr Opin Support Palliat Care (2012) 0.88
Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. Osteoporos Int (2012) 0.86
Atypical femoral fractures. Clin Cases Miner Bone Metab (2013) 0.86
Atypical femur fractures: a review of the evidence and its implication to clinical practice. Ther Adv Musculoskelet Dis (2011) 0.83
Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries. Osteoporos Int (2014) 0.82
Long-term safety concerns of antiresorptive therapy. Rheum Dis Clin North Am (2011) 0.81
Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation. J Cell Physiol (2015) 0.79
Alendronate-Related Femoral Fracture in a premenopausal glucocorticoid treated patient. Caspian J Intern Med (2014) 0.78
Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications. Ther Adv Chronic Dis (2015) 0.78
Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: sensitivity and trim and fill studies. Genet Test Mol Biomarkers (2013) 0.76
Atypical femoral fractures in association with bisphosphonate therapy: a case series. Emerg Radiol (2014) 0.76
Bisphosphonates and atypical subtrochanteric fractures of the femur. Bone Joint Res (2017) 0.75
The effect of alendronate treatment on cortical thickness of the proximal femur in postmenopausal women. Med J Islam Repub Iran (2016) 0.75
Questioning the association between bisphosphonates and atypical femoral fractures. Ann N Y Acad Sci (2014) 0.75
Atypical subtrochanteric fractures in Korean hip fracture study. Osteoporos Int (2017) 0.75
Sensitivity and specificity of radiographic characteristics in atypical femoral fractures. Osteoporos Int (2016) 0.75
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol (1992) 60.45
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med (1998) 32.43
Estimating causal effects from large data sets using propensity scores. Ann Intern Med (1997) 19.65
The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med (1978) 15.13
Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol (2003) 11.24
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab (2004) 8.36
Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol (2001) 7.04
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med (2008) 4.81
The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med (1994) 4.55
Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma (2008) 3.74
Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab (2010) 2.70
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res (2009) 2.65
Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care (2007) 2.31
Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am (2009) 2.19
A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf (2010) 1.95
Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf (2009) 1.68
Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop (2009) 1.64
Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int (2009) 1.63
Surgical management of hip fractures: an evidence-based review of the literature. I: femoral neck fractures. J Am Acad Orthop Surg (2008) 1.44
Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int (2009) 1.41
More on atypical fractures of the femoral diaphysis. N Engl J Med (2008) 1.21
Osteoporosis treatments and adverse events. Curr Opin Rheumatol (2009) 1.20
Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am (2002) 0.99
Alendronate-related femoral diaphysis fracture--what should be done to predict and prevent subsequent fracture of the contralateral side? Osteoporos Int (2009) 0.93
More on atypical fractures of the femoral diaphysis. N Engl J Med (2008) 0.87
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum (2008) 19.80
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res (2007) 14.84
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med (2005) 8.44
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum (2003) 6.68
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57
Surgery versus physical therapy for a meniscal tear and osteoarthritis. N Engl J Med (2013) 6.08
Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med (2014) 4.99
Development of the QuickDASH: comparison of three item-reduction approaches. J Bone Joint Surg Am (2005) 4.90
The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One (2010) 4.75
Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol (2006) 4.70
Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med (2004) 4.68
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
The comparative safety of analgesics in older adults with arthritis. Arch Intern Med (2010) 4.47
Rates and outcomes of primary and revision total hip replacement in the United States medicare population. J Bone Joint Surg Am (2003) 4.38
The importance of patient expectations in predicting functional outcomes after total joint arthroplasty. J Rheumatol (2002) 4.16
A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol (2011) 3.98
Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should. AIDS (2010) 3.93
Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA (2010) 3.85
Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med (2009) 3.84
Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol (2007) 3.82
The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med (2010) 3.78
Predicting the outcome of total knee arthroplasty. J Bone Joint Surg Am (2004) 3.70
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology (2006) 3.54
Incidence rates of dislocation, pulmonary embolism, and deep infection during the first six months after elective total hip replacement. J Bone Joint Surg Am (2003) 3.33
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33
Timing of total joint replacement affects clinical outcomes among patients with osteoarthritis of the hip or knee. Arthritis Rheum (2002) 3.29
The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med (2011) 3.27
Group exercise, education, and combination self-management in women with fibromyalgia: a randomized trial. Arch Intern Med (2007) 3.20
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09
Incentives for drug development--the curious case of colchicine. N Engl J Med (2010) 3.06
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA (2011) 3.02
Confounding control in healthcare database research: challenges and potential approaches. Med Care (2010) 3.01
The dramatic increase in total knee replacement utilization rates in the United States cannot be fully explained by growth in population size and the obesity epidemic. J Bone Joint Surg Am (2012) 2.98
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 2.98
Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91
Development of classification and response criteria for rheumatic diseases. Arthritis Rheum (2006) 2.88
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum (2010) 2.88
Hetastarch and bleeding complications after coronary artery surgery. Chest (2003) 2.87
Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med (2002) 2.82
Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol (2006) 2.81
Trends in epidemiology of knee arthroplasty in the United States, 1990-2000. Arthritis Rheum (2005) 2.76
Revising expectations from rapid HIV tests in the emergency department. Ann Intern Med (2008) 2.74
Accuracy of Medicare claims data for rheumatologic diagnoses in total hip replacement recipients. J Clin Epidemiol (2003) 2.72
The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med (2010) 2.71
Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA (2010) 2.71
The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf (2012) 2.70
Epidemiology of total knee replacement in the United States Medicare population. J Bone Joint Surg Am (2005) 2.67
Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis (2005) 2.65
Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol (2008) 2.58
Performance of propensity score calibration--a simulation study. Am J Epidemiol (2007) 2.56
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol (2005) 2.55
Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J (2007) 2.55
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med (2004) 2.52
Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. J Clin Epidemiol (2006) 2.51
Evaluating uses of data mining techniques in propensity score estimation: a simulation study. Pharmacoepidemiol Drug Saf (2008) 2.42
Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis (2013) 2.42
Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum (2007) 2.41
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med (2008) 2.40
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis (2010) 2.39
Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology (2005) 2.38
Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.37
Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med (2011) 2.35
Racial differences in screening for prostate cancer in the elderly. Arch Intern Med (2004) 2.34
Arthritis self-management education programs: a meta-analysis of the effect on pain and disability. Arthritis Rheum (2003) 2.30
Rotator cuff disorders: recognition and management among patients with shoulder pain. Arthritis Rheum (2004) 2.28
Preference-based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results. Int J Biostat (2007) 2.24
Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther (2011) 2.24
Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol (2011) 2.20
Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum (2007) 2.18
Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA (2011) 2.17
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 2.15
Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol (2012) 2.14
Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med (2012) 2.13
Assessing health state utilities in elderly patients at cardiovascular risk. Med Decis Making (2006) 2.12